Valuation: Outlook Therapeutics, Inc.

Market Cap 19Cr 17Cr 16Cr 14Cr 27Cr 1.82TCr 28Cr 186.25Cr 72Cr 896.63Cr 72Cr 71Cr 3.12TCr P/E 2026 *
-3.24x
P/E 2027 * -5.3x
Enterprise Value 19Cr 17Cr 16Cr 14Cr 27Cr 1.82TCr 28Cr 186.25Cr 72Cr 896.63Cr 72Cr 71Cr 3.12TCr EV / Sales 2026 *
160x
EV / Sales 2027 * 4.2x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day-5.92%
1 week-6.47%
1 month+117.81%
3 months+672.59%
6 months+0.63%
Current year+0.63%
1 week 1.53
Extreme 1.5302
1.79
1 month 0.68
Extreme 0.6752
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
02/06Buy

Director

29,000 0.0181%
28/05
Gms Ventures & Investments
BuyCompany 3,95,16,849 24.6751%
27/05Buy

Chairman

1,22,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
-5.92%-6.47%-0.62%-95.43% 19Cr
+2.02%+5.19%-1.45%+4.99% 4.72TCr
-2.77%+10.48%+409.05%+600.11% 3.98TCr
-0.03%+12.81%+22.61%-14.04% 3.22TCr
-1.73%+3.20%+17.72%+59.83% 3.17TCr
-3.29%+7.98%+14.01%+29.96% 2.46TCr
+1.15%+11.79% - - 1.66TCr
-0.96%+11.85%+68.73%+120.51% 1.51TCr
-0.50%+1.82%+12.27%+17.17% 1.37TCr
-1.74%+4.34%+100.68%+93.25% 1.31TCr
Average -1.37%+5.94%+71.45%+90.70% 2.34TCr
Weighted average by Cap. -0.76%+7.35%+93.65%+135.87%

Financials

2026 *2027 *
Net sales 12L 10.5L 10L 9L 17.04L 11Cr 17.35L 1.16Cr 45.15L 5.6Cr 45.08L 44.08L 20Cr 4.57Cr 4Cr 3.69Cr 3.45Cr 6.49Cr 432.36Cr 6.61Cr 44Cr 17Cr 213.35Cr 17Cr 17Cr 743.28Cr
Net income -5.22Cr -4.57Cr -4.22Cr -3.93Cr -7.41Cr -493.37Cr -7.54Cr -51Cr -20Cr -243.46Cr -20Cr -19Cr -848.16Cr -4.23Cr -3.71Cr -3.42Cr -3.19Cr -6.01Cr -400.24Cr -6.12Cr -41Cr -16Cr -197.51Cr -16Cr -16Cr -688.06Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
30/26/30 $1.590 -5.92% 58,76,727
29/26/29 $1.690 -1.17% 79,24,993
26/26/26 $1.710 +6.21% 1,14,91,945
25/26/25 $1.610 -4.17% 91,47,785
24/26/24 $1.680 -1.18% 86,76,520
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.590USD
Average target price
5.500USD
Spread / Average Target
+245.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock